Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against uniQure N.V.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is uniQure N.V. (QURE) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE). Investors who purchased uniQure securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether uniQure has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On September 29, 2026, uniQure released 48-month clinical data for AMT-130, its investigational gene therapy for Huntington’s disease. Although the Company reported continued evidence of slowed disease progression, the four-year results did not meet a key statistical measure and appeared less favorable than the earlier three-year data that had been used to support a Biologics License Application. The results raised investor concerns regarding the therapy’s long-term durability and prospects for regulatory approval. Following this news, uniQure’s stock price opened down nearly 40% on September 29, 2026.
What Should uniQure N.V. (QURE) Investors Do?
If you are aware of any facts relating to this investigation or purchased uniQure securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Is uniQure N.V. (NASDAQ: QURE) Stock Trading Today?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”